Recent Updates
Recently added Catalysts
RLMD

Relmada Therapeutics, Inc. Proforma Balance Sheet

Thursday, July 18, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Relmada Therapeutics, Inc. Proforma Balance Sheet March 31, 2019 Without Impact of Financings Pro Forma Adjustments Resulting from Financings Post Pro- Forma Adjustments ($ in thousands) Assets: Current $ 2,330,300 $ 10,855,700 a $ 13,186,000 b Non-cur

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+97%
120-day peak, hindsight
Typical move
17.7%
average across 7 past catalysts
Cash runway
~68 mo
Minimal dilution risk
Lead asset
REL-1017
Phase 3 · Major Depressive Disorder

Full Press Release Details

Relmada Therapeutics, Inc.
Proforma Balance Sheet
March 31, 2019
Without Impact of Financings Pro Forma Adjustments Resulting from Financings Post Pro- Forma Adjustments
($ in thousands)
Assets:
Current $ 2,330,300 $ 10,855,700 a $ 13,186,000 b
Non-current 273,427 - 273,427
Total assets 2,603,727 10,855,700 13,459,427
Liabilities and stockholders' equity:
Current 2,129,829 - 2,129,829
Non-current - - -
Total Liabilities 2,129,829 - 2,129,829
Stockholders' equity 473,898 10,855,700 11,329,598
Total liabilities and stockholders' equity $ 2,603,727 $ 10,855,700 $ 13,459,427
ShareAdd on Google
Tags: RLMD Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 18, 2019

Biotech snapshot

Cash runway
$218M liquidity · $3M/mo burn
~68 mo
Minimal dilution risk
Lead asset
REL-1017Phase 3
Major Depressive Disorder →

Catalyst track record

+97%
best trade around RLMD's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for RLMD.

See every catalyst's timing & PoA →